HEPATOTOXICITY, INCLUDING HEPATIC VENOOCCLUSIVE DISEASE (ALSO KNOWN AS SINUSOIDAL OBSTRUCTION SYNDROME) and INCREASED RISK OF POSTHEMATOPOIETIC STEM CELL TRANSPLANT NONRELAPSE MORTALITY
See full prescribing information for complete boxed warning.
- TRADE NAME: Besponsa (Wyeth)
- INDICATIONS: Relapsed or refractory B-cell precursor acute lymphoblastic leukemia
- CLASS: Antibody-drug conjugate (ADC), CD22-directed antibody-drug conjugate
- HALF-LIFE: 12 days
- FDA APPROVAL DATE: 08/17/2017
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
None known - PREGNANCY: Can cause fetal harm
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 07/31/2023
